Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments
- 1 December 2004
- journal article
- Published by Elsevier in Diabetes & Metabolism
- Vol. 30 (6), 549-556
- https://doi.org/10.1016/s1262-3636(07)70154-4
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to FranceDiabetes & Metabolism, 2003
- The Cost Effectiveness of Apligraf?? Treatment of Diabetic Foot UlcersPharmacoEconomics, 2003
- Diabetic foot ulcers: a quality of life issueDiabetes/Metabolism Research and Reviews, 2001
- Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.PharmacoEconomics, 2001
- The Cost-effectiveness of Treating Diabetic Lower Extremity Ulcers with Becaplermin (Regranex): A Core Model with an Application Using Swedish Cost DataValue in Health, 2000
- International consensus and practical guidelines on the management and the prevention of the diabetic footDiabetes/Metabolism Research and Reviews, 2000
- Estimating parametric relationships between health description and health valuation with an application to the EuroQol EQ-5DJournal of Health Economics, 1999
- Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group.Diabetes Care, 1999
- The burden of diabetic foot ulcersThe American Journal of Surgery, 1998
- Modeling Valuations for EuroQol Health StatesMedical Care, 1997